RU2659171C2 - Способ лечения лимфомы, применяя тиенотриазолодиазепиновые соединения - Google Patents
Способ лечения лимфомы, применяя тиенотриазолодиазепиновые соединения Download PDFInfo
- Publication number
- RU2659171C2 RU2659171C2 RU2015101106A RU2015101106A RU2659171C2 RU 2659171 C2 RU2659171 C2 RU 2659171C2 RU 2015101106 A RU2015101106 A RU 2015101106A RU 2015101106 A RU2015101106 A RU 2015101106A RU 2659171 C2 RU2659171 C2 RU 2659171C2
- Authority
- RU
- Russia
- Prior art keywords
- cell
- formula
- lymphoma
- compound
- patient
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 26
- 206010025323 Lymphomas Diseases 0.000 title claims abstract description 18
- 150000001875 compounds Chemical class 0.000 title claims description 71
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 29
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 23
- GNMUEVRJHCWKTO-FQEVSTJZSA-N 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NC1=CC=C(O)C=C1 GNMUEVRJHCWKTO-FQEVSTJZSA-N 0.000 claims abstract description 9
- 230000003211 malignant effect Effects 0.000 claims abstract description 8
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 210000000952 spleen Anatomy 0.000 claims description 5
- 150000004683 dihydrates Chemical class 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 59
- 206010042971 T-cell lymphoma Diseases 0.000 abstract description 13
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 abstract description 13
- 230000014509 gene expression Effects 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 9
- 102100038895 Myc proto-oncogene protein Human genes 0.000 abstract description 6
- 101710135898 Myc proto-oncogene protein Proteins 0.000 abstract description 3
- 101710150448 Transcriptional regulator Myc Proteins 0.000 abstract description 3
- 229950000080 birabresib Drugs 0.000 abstract description 3
- 231100000433 cytotoxic Toxicity 0.000 abstract description 3
- 230000001472 cytotoxic effect Effects 0.000 abstract description 3
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 abstract description 3
- 108700020796 Oncogene Proteins 0.000 abstract description 2
- 108091023040 Transcription factor Proteins 0.000 abstract description 2
- 102000040945 Transcription factor Human genes 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 41
- 230000036210 malignancy Effects 0.000 description 40
- 125000004432 carbon atom Chemical group C* 0.000 description 24
- 108020004999 messenger RNA Proteins 0.000 description 22
- 125000000217 alkyl group Chemical group 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 102100033641 Bromodomain-containing protein 2 Human genes 0.000 description 13
- 101000871850 Homo sapiens Bromodomain-containing protein 2 Proteins 0.000 description 13
- 125000005843 halogen group Chemical group 0.000 description 12
- 101150092565 DOHH gene Proteins 0.000 description 10
- 108091005625 BRD4 Proteins 0.000 description 9
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 description 9
- 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
- 208000003950 B-cell lymphoma Diseases 0.000 description 7
- 102100033642 Bromodomain-containing protein 3 Human genes 0.000 description 7
- 101000871851 Homo sapiens Bromodomain-containing protein 3 Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 208000017604 Hodgkin disease Diseases 0.000 description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- -1 methyl (S) - {4- (3'-cyanobiphenyl-4-yl) -2,3,9-trimethyl-6H-thieno [3,2- f] [1,2,4] triazolo [4,3-a] [1,4] diazepin-6-yl} acetate Chemical compound 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 125000004076 pyridyl group Chemical group 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 5
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 5
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000001805 Bromodomains Human genes 0.000 description 4
- 108050009021 Bromodomains Proteins 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 4
- 230000009036 growth inhibition Effects 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 4
- 208000021937 marginal zone lymphoma Diseases 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000032677 cell aging Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 2
- 206010003908 B-cell small lymphocytic lymphoma Diseases 0.000 description 2
- 108700003785 Baculoviral IAP Repeat-Containing 3 Proteins 0.000 description 2
- 102000051819 Baculoviral IAP Repeat-Containing 3 Human genes 0.000 description 2
- 101150104237 Birc3 gene Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108091028690 C-myc mRNA Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000002464 Galactosidases Human genes 0.000 description 2
- 108010093031 Galactosidases Proteins 0.000 description 2
- 208000017605 Hodgkin disease nodular sclerosis Diseases 0.000 description 2
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 description 2
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 description 2
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 2
- 206010025327 Lymphopenia Diseases 0.000 description 2
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 101100379220 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) API2 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 2
- 208000000389 T-cell leukemia Diseases 0.000 description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000013056 classic Hodgkin lymphoma Diseases 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 2
- 231100001023 lymphopenia Toxicity 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- FGNAJWFZOBYZLR-UHFFFAOYSA-N 3h-[1,2,4]triazolo[4,3-a][1,4]diazepine Chemical compound N1=CC=CN2CN=NC2=C1 FGNAJWFZOBYZLR-UHFFFAOYSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- 208000012526 B-cell neoplasm Diseases 0.000 description 1
- 241000208199 Buxus sempervirens Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010087705 Proto-Oncogene Proteins c-myc Proteins 0.000 description 1
- 102000009092 Proto-Oncogene Proteins c-myc Human genes 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000012721 SDS lysis buffer Substances 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229940125763 bromodomain inhibitor Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010807 real-time PCR kit Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261663885P | 2012-06-25 | 2012-06-25 | |
| US61/663,885 | 2012-06-25 | ||
| US201261670918P | 2012-07-12 | 2012-07-12 | |
| US61/670,918 | 2012-07-12 | ||
| PCT/EP2013/063313 WO2014001356A1 (en) | 2012-06-25 | 2013-06-25 | Method of treating lymphoma using thienotriazolodiazepine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015101106A RU2015101106A (ru) | 2016-08-10 |
| RU2659171C2 true RU2659171C2 (ru) | 2018-06-28 |
Family
ID=48672651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015101106A RU2659171C2 (ru) | 2012-06-25 | 2013-06-25 | Способ лечения лимфомы, применяя тиенотриазолодиазепиновые соединения |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140018353A1 (OSRAM) |
| EP (1) | EP2863923B1 (OSRAM) |
| JP (1) | JP6265979B2 (OSRAM) |
| KR (1) | KR20150045423A (OSRAM) |
| CN (1) | CN105050605A (OSRAM) |
| AU (1) | AU2013283378B2 (OSRAM) |
| BR (1) | BR112014032105A2 (OSRAM) |
| CA (1) | CA2877434A1 (OSRAM) |
| IN (1) | IN2014DN11269A (OSRAM) |
| MX (1) | MX2014015986A (OSRAM) |
| RU (1) | RU2659171C2 (OSRAM) |
| WO (1) | WO2014001356A1 (OSRAM) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1208875A1 (en) | 2012-01-12 | 2016-03-18 | 耶鲁大学 | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase |
| MX366703B (es) | 2013-03-15 | 2019-07-22 | Incyte Holdings Corp | Heterociclos tricíclicos como inhibidores de la proteína bet. |
| EP3019502B1 (en) | 2013-07-08 | 2017-05-17 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
| US9795612B2 (en) * | 2013-08-01 | 2017-10-24 | Merck Sharp & Dohme Corp. | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
| KR20160037201A (ko) * | 2013-08-06 | 2016-04-05 | 온코에틱스 게엠베하 | Bet-브로모도메인 억제제를 사용한 미만성 거대 b-세포 림프종 (dlbcl)의 치료 방법 |
| WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
| WO2015018520A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma |
| WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| WO2015078929A1 (en) * | 2013-11-27 | 2015-06-04 | Oncoethix Sa | Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds |
| WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| KR102702503B1 (ko) | 2014-04-23 | 2024-09-05 | 인사이트 홀딩스 코포레이션 | BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온 |
| WO2015168555A1 (en) * | 2014-05-02 | 2015-11-05 | Oncoethix Sa | Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds |
| JP2017514909A (ja) | 2014-05-02 | 2017-06-08 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を用いる急性骨髄性白血病及び／又は急性リンパ芽球性白血病の治療方法 |
| MX2016014574A (es) | 2014-05-08 | 2017-02-23 | Oncoethix Gmbh | El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo. |
| EP3154549A1 (en) | 2014-06-13 | 2017-04-19 | Oncoethix GmbH | Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds |
| JP2017528446A (ja) * | 2014-08-19 | 2017-09-28 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を用いるリンパ腫の治療方法 |
| WO2016044130A1 (en) | 2014-09-15 | 2016-03-24 | Incyte Corporation | Tricyclic heterocycles for use as bet protein inhibitors |
| KR101675984B1 (ko) | 2015-02-23 | 2016-11-14 | 한양대학교 에리카산학협력단 | 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 약학적 조성물 |
| CN108601764A (zh) | 2015-03-18 | 2018-09-28 | 阿尔维纳斯股份有限公司 | 用于靶蛋白的增强降解的化合物和方法 |
| US10683305B2 (en) | 2015-04-27 | 2020-06-16 | Concert Pharmaceuticals, Inc. | Deuterated OTX-015 |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| US20170121347A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| PH12021551886A1 (en) | 2016-06-20 | 2023-07-17 | Incyte Corp | Crystalline solid forms of a bet inhibitor |
| CA3050309A1 (en) | 2017-01-31 | 2018-08-09 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| EP3743066A4 (en) | 2018-01-26 | 2021-09-08 | Yale University | IMIDE-BASED PROTEOLYSIS MODULATORS AND RELATED METHODS OF USE |
| CN108070562A (zh) * | 2018-02-03 | 2018-05-25 | 金华市中心医院 | 一种“双打击”弥漫大b细胞淋巴瘤细胞系制备方法 |
| JP2021521192A (ja) | 2018-04-13 | 2021-08-26 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | セレブロンリガンドおよび同リガンドを含む二機能性化合物 |
| JP7526721B2 (ja) | 2018-09-11 | 2024-08-01 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 癌治療のためのブロモドメインＢＲＤ４阻害剤としてのｔｅｒｔ－ブチル（Ｓ）－２－（４－（フェニル）－６Ｈ－チエノ［３，２－ｆ］［１，２，４］トリアゾロ［４，３－ａ］［１，４］ジアゼピン－６－イル）アセテート誘導体及び関連化合物 |
| CR20220353A (es) | 2019-12-19 | 2022-10-20 | Arvinas Operations Inc | Compuestos y métodos para la degradación dirigida del receptor de andrógenos |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| WO2025049555A1 (en) | 2023-08-31 | 2025-03-06 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0989131A1 (en) * | 1996-09-13 | 2000-03-29 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienotriazolodiazepine compounds and medicinal uses thereof |
| EP2239264A1 (en) * | 2007-12-28 | 2010-10-13 | Mitsubishi Tanabe Pharma Corporation | Antitumor agent |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994006802A1 (fr) | 1992-09-18 | 1994-03-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose de thienodiazepine et son utilisation medicinale |
| JP5715241B2 (ja) * | 2010-05-14 | 2015-05-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法 |
| DK2571503T3 (en) * | 2010-05-14 | 2015-04-20 | Dana Farber Cancer Inst Inc | COMPOSITIONS AND THEIR USE IN THE TREATMENT OF NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS |
| US10071129B2 (en) * | 2011-08-30 | 2018-09-11 | Whitehead Institute For Biomedical Research Dana-Farber Cancer Institute, Inc. | Method for identifying bromodomain inhibitors |
-
2013
- 2013-06-25 BR BR112014032105A patent/BR112014032105A2/pt not_active Application Discontinuation
- 2013-06-25 JP JP2015517810A patent/JP6265979B2/ja not_active Expired - Fee Related
- 2013-06-25 CN CN201380045846.0A patent/CN105050605A/zh active Pending
- 2013-06-25 RU RU2015101106A patent/RU2659171C2/ru not_active IP Right Cessation
- 2013-06-25 EP EP13730912.6A patent/EP2863923B1/en not_active Not-in-force
- 2013-06-25 IN IN11269DEN2014 patent/IN2014DN11269A/en unknown
- 2013-06-25 US US13/926,029 patent/US20140018353A1/en not_active Abandoned
- 2013-06-25 WO PCT/EP2013/063313 patent/WO2014001356A1/en not_active Ceased
- 2013-06-25 MX MX2014015986A patent/MX2014015986A/es unknown
- 2013-06-25 CA CA2877434A patent/CA2877434A1/en not_active Abandoned
- 2013-06-25 AU AU2013283378A patent/AU2013283378B2/en not_active Ceased
- 2013-06-25 KR KR20157000782A patent/KR20150045423A/ko not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0989131A1 (en) * | 1996-09-13 | 2000-03-29 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienotriazolodiazepine compounds and medicinal uses thereof |
| EP2239264A1 (en) * | 2007-12-28 | 2010-10-13 | Mitsubishi Tanabe Pharma Corporation | Antitumor agent |
Non-Patent Citations (2)
| Title |
|---|
| FILIPPAKOPOULOS P ET AL: "Selective inhibition of BET bromodomains", NATURE 20101223 NATURE PUBLISHING GROUP GBR LNKD- DOI:10.1038/NATURE09504, vol. 468, no. 7327, 23 December 2010 (2010-12-23), pages 1067-1073, , [он лайн] [найдено 10.11.2016] Найдено из интернет: http://www.nature.com/nature/journal/v468/n7327/abs/nature09504.html. * |
| FILIPPAKOPOULOS P ET AL: "Selective inhibition of BET bromodomains", NATURE 20101223 NATURE PUBLISHING GROUP GBR LNKD- DOI:10.1038/NATURE09504, vol. 468, no. 7327, 23 December 2010 (2010-12-23), pages 1067-1073, реферат, [он лайн] [найдено 10.11.2016] Найдено из интернет: http://www.nature.com/nature/journal/v468/n7327/abs/nature09504.html. * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014015986A (es) | 2016-02-11 |
| JP2015531747A (ja) | 2015-11-05 |
| IN2014DN11269A (OSRAM) | 2015-10-09 |
| RU2015101106A (ru) | 2016-08-10 |
| KR20150045423A (ko) | 2015-04-28 |
| CN105050605A (zh) | 2015-11-11 |
| AU2013283378A1 (en) | 2015-01-29 |
| US20140018353A1 (en) | 2014-01-16 |
| BR112014032105A2 (pt) | 2017-08-01 |
| WO2014001356A1 (en) | 2014-01-03 |
| CA2877434A1 (en) | 2014-01-03 |
| EP2863923B1 (en) | 2019-05-08 |
| AU2013283378B2 (en) | 2017-07-13 |
| JP6265979B2 (ja) | 2018-01-24 |
| EP2863923A1 (en) | 2015-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2659171C2 (ru) | Способ лечения лимфомы, применяя тиенотриазолодиазепиновые соединения | |
| EP2282779B1 (en) | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response | |
| EP2916868B1 (en) | Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor | |
| CN101910182A (zh) | 抗癌剂 | |
| EP1778224A2 (en) | Flt3 inhibitors for immune suppression | |
| AU2023210543B2 (en) | Uses of myostatin antagonists, combinations containing them and uses thereof | |
| Xu et al. | Pharmacological characterization of H05, a novel serotonin and noradrenaline reuptake inhibitor with moderate 5-HT2A antagonist activity for the treatment of depression | |
| CA2576159A1 (en) | Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases | |
| WO2013138600A1 (en) | Radioprotector compounds | |
| AU2014308700A1 (en) | Cancer treatment | |
| US20240238284A1 (en) | Compounds and compositions for the treatment of mpnst | |
| Ten Broeke et al. | Specific modulation of calmodulin activity induces a dramatic production of superoxide by alveolar macrophages | |
| Zuo et al. | BRD4 inhibition sensitizes aggressive non-Hodgkin lymphomas to PI3Kδ inhibitors by suppressing PI3K reactivation and c-MYC expression | |
| EP3664787B1 (en) | Use of selective serotonin 5-ht1a receptor agonists for treating side-effects of vmat inhibitors | |
| EP2908820A1 (en) | Treatment of pulmonary fibrosis using an inhibitor of cbp/catenin | |
| Zhang et al. | Astaxanthin suppress ferroptosis through the Akt1-FoxO3a signaling pathway to alleviates brain injury after intracerebral hemorrhage | |
| Zuo et al. | Inhibition of Bromodomain-Containing 4 Sensitises Aggressive Non-Hodgkin Lymphomas to Phosphatidylinositol 3-Kinase δ Inhibitors | |
| EP3630093B1 (en) | Treatment of diseases associated with a dysregulation of the mtor pathway | |
| Zhou | Determination the Role of Constitutive Nitric Oxide Synthase in Skin Carcinogenesis Post UV Irradiation | |
| Allen | Identifying Novel mTORC1 Inhibitors and AMPK Stimulators as Therapeutics | |
| AU2003277969B2 (en) | Aminated isoflavonoid derivatives and uses thereof | |
| WO2014110277A1 (en) | Methods of treating developmental and personality disorders | |
| WO2018140923A1 (en) | Methods of treating cancer | |
| HK1254300A1 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20190626 |